CA2037610A1 - Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application - Google Patents

Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application

Info

Publication number
CA2037610A1
CA2037610A1 CA002037610A CA2037610A CA2037610A1 CA 2037610 A1 CA2037610 A1 CA 2037610A1 CA 002037610 A CA002037610 A CA 002037610A CA 2037610 A CA2037610 A CA 2037610A CA 2037610 A1 CA2037610 A1 CA 2037610A1
Authority
CA
Canada
Prior art keywords
aminomethyl
hydrochloride
methyl
general formula
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002037610A
Other languages
French (fr)
Inventor
Pascal George
Jacques Froissant
Mireille Sevrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Publication of CA2037610A1 publication Critical patent/CA2037610A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Abstract

ABSTRACT

DERIVATIVES OF 4-(AMINOMETHYL)PIPERIDINE, THEIR
PREPARATION AND THEIR THERAPEUTIC APPLICATION

Compounds of general formula (I) (I) in which n is 1 or 2;
R represents a linear or branched C1-C3-alkyl group; and X represents at least one substituent chosen from hydrogen, halogsn, C1-C3-alkyl and C1-C3-alkoxy, in the form of a free base or an acid addition salt thereof, and their therapeutic application.

Description

DERIVATIVES OF 4-(AMINOMETHYL)PIPERIDINE. THEIR
PREPARATION AND THEIR THERAPEUTIC APPLICATION
The present invention relates to derivatives of 4-(aminomethyl)piperidine, their preparation and their therapeutic application.
The invention provides a compound which is a 4-(aminomethyl)piperidine derivative of general formula (I) (CH2)n /R

N ~ (I~
~,X

in which n is 1 or 2;
R represents a linear or branched Cl-C3-alkyl group; and X represents at least one substituent selected from hydrogen, halogen, C1-C3-alkyl and C1-C3-alkoxy;
in the form of a free base or an acid addition salt thereof.
In a preferred embodiment of the invention, R is methyl or n-propyl, X is hydrogen, chlorine, methyl, methoxy or ethoxy and any acid addition salt is the ;~037f~10 hydrochloride.
Examples of specific compounds of the invention are:
4-[N-(indan-2-yl)-N-methyl]aminomethyl-1-benzoylpiperidine hydrochloride;4-[N-(indan-2-yl)-N-propyl]aminomethyl-l-benzoylpiperidine hydrochloride;
4-tN-(1,2,3,4-tetrahydronaphthalen-2-yl)-N-methyl]aminomethyl-l-benzoylpiperidine hydrochloride;
and 4-[N-(1,2,3,4-tetrahydronaphthalen-2-yl)-N-propyl]aminomethyl-1-benzoylpiperidine hydrochloride.
The invention further provides a process for the preparation of compounds of general formula (I), which comprises reacting a primary amine of general formula (II) (CH2)n ~ NH2 (II) (in which n is as hereinbefore defined), which may be in the form of an acid addition salt, (a) with an alkyl or benzyl chloroformate; or (b) with a C2 or C3 acid chloride;
reducing the carbamate (a) or the amide (b) thus obtained to give a secondary amine of general formula (III) 203~76~V

(CHZ)n ,/
~ ~ N~ (III) ~V

(in which R is as hereinbefore defined), and reacting this secondary amine with a tosylate of general formula (IV) ~ N ~ (IV) ~X

S (in which Ts represents a (4-methylphenyl)sulphonyl group and X is as hereinbefore defined), if appropriate in the presence of an organic or inorganic base, and if desired converting a free base of formula I into an acid addition salt.

ZC)3~

The process of the invention is illustrated by the reaction scheme given below:

Reaction Scheme (CH2)n / \ (II) ~NH2 , .

(CH2)n R
( III ) NH

'rsO CN ~IV) (C~z)~

~ ~ N ~ (I) ~X

Steps (a) and (b) may be carried out in an inert aprotic solvent such as toluene, tetrahydrofuran, or a halogenated solvent, for example dichloromethane, and in the presence of an organic base such as a tertiary amine, for example triethylamine.

;~();~'7610 In the first case (a), an alkyl or benzyl carbamate is obtained which, by means of reduction, for example with lithium aluminium hydride, in an ethereal solvent such as tetrahydrofuran, gives a secondary amine of general formula (III) in which R represents a methyl group. In the second case (b), an amide is obtained which, by reduction, for example with lithium aluminium hydride, in an ethereal solvent such as tetrahydro- furan, gives a secondary amine of general formula (III) in which R represents a C2 or C3 alkyl group.
The secondary amine (III) is then reacted with a tosylate of formula (IV) (in which Ts represents a (4-methylphenyl)sulphonyl group), optionally in the presence of an inert solvent such as dimethylformamide, toluene or xylene, at a temperature of 20 to 150~C, and if appropriate in the presence of an organic base, such as a tertiary amine, or inorganic base, such as an alkali metal carbonate or hydrogen-carbonate.
The starting amine of general formula (II) in which n = 1 is commercially available (2-aminoindan): the starting amine of general formula (II) in which n = 2 can be prepared according to known methods, starting from 3,4-dihydro(lH)naphthalen-2-one, which is commercially available, by reaction with hydroxylamine hydrochloride in the presence of sodium acetate, then catalytic hydrogenation of the intermediate oxime.

;~ 610 The tosylate of formula (IV) can be prepared, for example, as described in EP-A-0,306,375.
The following Examples illustrate in detail the preparation of some compounds according to the invention.
The elemental microanalyses and the IR and NMR spectra confirm the structures of the products obtained.

Example l 4-tN-~indan-2-yl)-N-methyl]aminomethyl-l-benzoylpiperidine hydrochloride.
a) Ethyl indan-2-carbamate.
200 ml of dichloromethane then 10 ml, i.e. 7.26 g (71.7 mmol) of triethylamine were added to 5 g (29.5 mmol) of 2-aminoindan hydrochloride. The mixture was stirred for 30 min, then 3.4 ml, i.e. 3.84 g (35.4 mmol) of ethyl chloroformate were added dropwise. The mixture was stirred for 30 min, then ice-water and an excess of lN hydrochloric acid were added. The precipitate was filtered, washed, dried and purified by chromatography on a silica gel column, eluted with an 8Q:20 mixture of dichloromethane/ethyl acetate. 4.25 g of amorphous solid were isc'ated.
Melting point: 68-68.5C.
b) 2-(N-methyl)aminoindan.
To a suspension of 1.13 g (30 mmol) of anhydrous lithium aluminium hydride in 150 ml of tetrahydrofuran was - 7 - Z03~ 0 added a solution of 2.2 g of ethyl indan-2-carbamate in 50 ml of the same solvent. The mixture was heated to reflux, allowed to cool, hydrolysed with an excess of aqueous lN
sodium hydroxide solution, and the mixture was filtered, concentrated and distilled at about 100 Pa at 150'C. 3.5 g of oil were obtained.
c) 4-tN-(indan-2-yl)-N-methyl]aminomethyl-1-benzoylpiperidine hydrochloride.
b mixture of 1.13 g (7.7 mmol) of 2-(N-methyl)-aminoindan and 2.9 g (7.7 mmol) of (1-benzoylpiperidin-4-yl)methyl 4-methylphenylsulphonate was heated under nitrogen in a 50 ml flask in an oil bath at 150C for 3 h.
The mixture was allowed to return to room temperature, and dichloromethane and an excess of aqueous lN sodium hydroxide solution were added. After the reaction medium had completely dissolved, the organic phase was separated, the solvent was evaporated and the residue was purified by chromatography on a silica gel column, eluted with a 97:3 mixture of dichloromethane/methanol. 1.3 g of amide were obtained, to which was added 3 ml of 1.7 M hydrochloric acid in ethanol, the mixture was stirred for 15 min and evaporated to dry~ess, and the solid was recrystallised in acetonitrile and then in acetone. 0.95 g of hydrochloride were finally isolated.
Melting point: 212-213'C.

~037610 Example 2 4-tN-(indan-2-yl)-N-propyl]aminomethyl-l-benzoylpiperidine hydrochloride.
a) N-(indan-2-yl)propionamide.
200 ml of dichloromethane, then 15 ml, i.e. 10.9 g (107.6 mmmol) of triethylamine were added to 5 g t29.5 mmol) of 2-aminoindan hydrochloride. The mixture was stirred, then 2.6 ml (29.5 mmol) of propionyl chloride were added and stirring was continued at room temperature for 12 h. Dilute hydrochloric acid was added, the precipitate was filtered, washed, dried and purified by chromatography on a silica gel column, eluted with an 80:20 mixture of dichloromethane/ethyl acetate. 4.87 g of beige solid were isolated.
b) 2-(N-propyl)aminoindan.
Under the conditions described in connection with 2-(N-methyl)aminoindan, 4.87 g (25.7 mmol) of N-(indan-2-yl)propionamide in tetrahydrofuran were reduced by means of 1.95 g (51.4 mmol) of lithium aluminium hydride. After distillation (~100 Pa, 135~C), 4.22 g of amine were obtained.
c) 4-[N-(indan-2-yl)-N-pro ~yl]aminomethyl-l-benzoylpiperidine hydrochloride.
A mixture of 2.28 g (13 mmol) of 2-(N-propyl)aminoindan and 5.0 g (14.4 mmol) of (1-benzoyl-piperidin-4-yl)methyl 4-methylsulphonate was heated at 203~61(~
_ g _ 170C for 2 h. The mixture was allowed to return to room temperature, and dichloromethane and an excess of aqueous lN sodium hydroxide solution were added. After the reaction medium had dissolved completely, the organic phase was separated, the solvent was evaporated and the residue was purified by chromatography on a silica gel column, eluted with a 97:3 mixture of dichloromethane/methanol. 1.48 g of viscous oil were obtained. 2.3 ml of 1.7 M hydrochloric acid in ethanol were added, the mixture was stirred for 30 min and evaporated to dryness, and the solid was recrystallised in acetone. 0.61 g of hydrochloride were finally isolated.
Melting point: 174-176C.
Example 3 4-~N-(1,2,3,4-tetrahydronaphthalen-2-yl)-N-methyl]aminomethyl-l-benzoylpiperidine hydrochloride.
a) 3,4-dihydro(lH)naphthalene-2-oxime.
A mixture of 12.34 g (84.4 mmol) of 3,4-dihydro(lH)naphthalen-2-one, 15.13 g (184.4 mmol) of sodium acetate and 9.97 g (143.5 mmol) of hydroxylamine hydrochloride in 250 ml of absolute ethanol was heated to reflux for 1 h. The mixture was con-entrated, water and diethyl ether were added, the organic phase was separated, washed with water and dried over sodium sulphate, and the solvent was evaporated. 13.45 g of orange oil were obtained.

Z03~610 b) 2-amino-1,2,3,4-tetrahydronaphthalene hydrochloride.
55 ml of 1.7 M ethanolic hydrogen chloride, 5 ml of chloroform and 0.3 g of platinum oxide were added to 13.45 g (83.4 mmol) of 3,4-dihydro-(lH)naphthalene-2-oxime, and the mixture was stirred, then subjected to hydrogenation under a pressure of about 0.31 MPa at room temperature for 4 h, then at 35-C for 10 h. The mixture was filtered, the filtrate was partly evaporated and the white solid which precipitated was filtered. After drying 3.22 g of hydrochloride were obtained.
c) Phenylmethyl 1,2,3,4-tetrahydronaphthalene-2-carbamate.
A mixture of 11.0 g of 2-amino-1,2,3,4-tetrahydronaphthalene hydrochloride, 200 ml of dichloromethane and 17.6 ml, i.e. 12.8 g (126 mmol) of triethylamine was stirred for 30 min. 10.3 ml (72.2 mmol) of phenylmethyl chloroformate were then added slowly, and stirring was continued for 12 h. Ice-water and an excess of lN hydrochloric acid were added. The precipitate was filtered, washed, dried and purified by chromatography on a column of silica gel, eluted with an 80:20 mixture of dichloromethane/ethyl acetate. 12.3 g of carbamate were isolated.
d) 2-(N-methyl)amino-1,2,3,4-tetrahydronaphthalene.
7.43 g (26.4 mmol) of phenylmethyl 1,2,3,4-tetrahydronaphthalene-2-carbamate were added in portions to a suspension of 4.5 g (26.4 mmol) of lithium aluminium Z03~6~0 hydride in 200 ml of tetrahydrofuran, and the mixture was heated to reflux for 3 h 30, allowed to cool, and hydrolysed with an excess of aqueous lN sodium hydroxide solution, the mixture was filtered and concentrated, and the residue was distilled at about 80 Pa between 140 and 240-C. 4.78 g of impure oil were obtained, which was utilised in its impure state in the following step.

e) 4-tN-(1,2,3,4-tetrahydronaphthalen-2-yl)-N-methyl]aminomethyl-l-benzoylpiperidine hydrochloride.
10.7 g (32 mmol) of (1-benzoylpiperidin-4-yl)methyl 4-methylphenylsulphonate were added to 4.78 g of the amine obtained above and the mixture was heated in an oil bath at 140C for 3 h. The mixture was allowed to return to room temperature, and dichloromethane and an excess of aqueous 1 N sodium hydroxide solution were added. After the reaction medium had dissolved completely, the organic phase was separated, the solvent was evaporated and the residue was purified by chromatography on a silica gel column, eluted with a 97:3 mixture of dichloromethane/methanol.
4.02 g of still impure material were obtained, to which 7 ml of 1.7 M hydrochloric acid in ethanol were added the mixture was stirred for 30 min and evaporated to dryness, and the solid was recrystallised in a mixture of toluene and acetonitrile, then in acetone. 0.84 g of white crystalline hydrochloride were finally isolated.

- 12 - ~0~6~0 Melting point: 223-225C.
Example 4 4-[N-(1,2,3,4-tetrahydronaphthalen-2-yl)-N-propyl]aminomethyl-l-benzoylpiperidine hydrochloride.
Working as in Example 3, but using 2-(N-propyl)amino-1,2,3,4-tetrahydronaphthalene as the amine of general formula (III) (prepared from 2-amino-1,2,3,4-tetrahydronaphthalene hydrochloride, according to the method described in Example 2, a and b), 4-[N-(1,2,3,4-tetrahydronaphthalen-2-yl)-N-propyl]aminomethyl-l-benzoylpiperidine hydrochloride was obtained.
Melting point: 200-202C.
The table which follows illustrates the chemical structures and the physical properties of some compounds according to the invention.
Table (CH2~n /R

~ X

~03~ 0 . ._ ~ . _ No . n R X Salt M . p . ( ~ C) . _ 1 1 CH3 11 Hc!l 212-213 2 1 n~3E~7 H HCl 174~1'16 3 2 CH3 ~ HCl 223-2~5 4 2 nC3H7 H ~ICl 2 00-2 02 1 aC3~7 4-F H~l 190-192 6 1 nC3H7 3-Cl HCl 151-154 7 1 nC3H7 3-CH3 HCl 147-14 8 8 1 aC3H7 3-OCH3 HC1 18~-190 g ~ nc3N7 3 0C2H5 HCl 2 00-2 03 5 ~ote: In the column "R", "n~3H7" denotes an n-propyl group; in the ~olumn "salt", "HCl" denotes a hydro~hloride.
The ~o~pound~ of the invention ha~e been ~ubmitted to a series of pharmacological tests which have revealed their utility as therapeutically active substances.
They have been the subject o~ a study with regard to their affini~y for ~erotoninergl~ receptors of the 5-HT1A type present in the hippoaampus of the rat.
The compounds di~place the binding of a speci~ic labelled 3S ligand, ~3H]-8-hydroxy~-di-n-propylaminotetralin (designated below by "~3H]-8-oH-DpAT~ and described by Gozlan et al., Nature, (1983), 305, 140-142) on the 5-HTlA

203~6~0 receptors. The animals used were male Sprague-Dawley rats weighing 160 to 200 g. After decapitation, the brain was removed and the hippocampus was dissected out. The tissue was ground in an Ultra-Turrax Polytro ~ apparatus for 30 s at half the maximum speed in 10 volumes of 50 mM tris buffer adjusted to pH 7.4 with hydrochloric acid (i.e.
100 mg of fresh tissue per ml). The homogenised tissues were washed twice at 4~C, by centrifuging them at 48,000 x g for 10 min each time and resuspending the pellets in fresh cold buffer. Finally, the last pellet was suspended in the buffer to give a concentration of 50 mg of starting tissue per ml of 50 mM buffer. The mixture was then incubated at 37C for 10 min.
The binding to ~3H]-8-oH-DpAT (1 nM) was determined by incubation of 50 ~1 of membrane suspension in a final volume of 250 ~1 of buffer containing 10 ~M pargyline and 3 ~M paroxetine. After incubation at 37C for 15 min, the membranes were recovered by filtration on Whatman GF/
filters which were washed three times with aliquot quantities of 5 ml of iced buffer. The filters were extracted in the scintillation liquid and the radioactivity was measured by liquid scintigraphy. The specific binding of [3H]-8-oH-DpAT was defined as the quantity of radioactive material retained on the filters and being able to be inhibited by co-incubation in 10 ~M
5-hydroxytryptamine. At a concentration of 1 nM [3H]-8-OH-X03~6~.0 DPAT, the specific binding represented 90 % of the total radioactivity recovered on the filter.
For each concentration of compound studied, the percentage inhibition of binding with t3H]-8-oH-DpAT was determined, then the concentration ~C50, the concentration which inhibits 50 % of the binding.
For the compounds of the invention, the IC50 lie between 0.001 and 0.1 ~M.
The central activity of the compounds of the invention was evaluated by their effects on the "PG0 (ponto-geniculo-occipital) spikes" induced by reserpine in the cat, according to the method described by H. Depoortere in Sleep 1976, 3rd Europ. Congr. Sleep Res., Montpellier 197fi, 358-361 (Karger, Basel 1977).
Cumulative doses of the compounds to be studied (from 0.001 to 3 mg/kg intravenously) were administered at intervals of 30 min, 4 h after intraperitoneal injection of a dose of 0.75 mg/kg of reserpine, to curarised cats under artificial ventilation. The electroencephalographic and phasic activities (PG0-R spikes) were recorded with the aid of cortical and deep (lateral geniculate) electrodes. For each dose of the compound studied, the percentage decrease in the number of PG0 spikes, then the AD50, the active dose which decreases this number of spikes by 50 %, were determined. For the compounds of the invention, the intravenous AD50 values lie between 0.001 and 1 mg/kg.

;~03 ~610 The results of the tests show that the compounds of the formula (I) possess, in vitro, a high affinity and a selectivity for 5-HTlA type serotoninergic receptors. In vivo, they show an agonist, partial agonist or antagonist activity, at these receptors.
The compounds of the invention may therefore be used for the treatment of diseases and conditions directly or indirectly involving the 5-HTlA type serotoninergic receptors, especially for the treatment of depressive states, anxiety states, sleep disorders, for the regulation of food intake, for the treatment or the prevention of vomiting and of motion sickness, and also for the treatment of vascular or cardiovascular disorders such as migraine and hypertension.
To this end, they can be formulated as pharmaceutical compositions in which they are the active ingredient. They can be presented in all forms appropriate to their administration orally or parenterally, in combination with all suitable excipients, and in doses permitting a daily dosage of 1 to 1,000 mg.

Claims (6)

1. A compound which is a 4-(aminomethyl)piperidine derivative of general formula (I) (I) in which n is 1 or 2;
R represents a linear or branched C1-C3-alkyl group; and X represents at least one substituent selected from hydrogen, halogen, C1-C3-alkyl and C1-C3-alkoxy;
in the form of a free base or an acid addition salt thereof.
2. A compound according to claim 1 wherein R is methyl or n-propyl, X is hydrogen, chlorine, methyl, methoxy or ethoxy and any acid addition salt is the hydrochloride.
3. A compound according to claim 1, which is:
4-[N-(indan-2-yl)-N-methyl]aminomethyl-1-benzoylpiperidine hydrochloride;
4-[N-(indan-2-yl)-N-propyl]aminomethyl-1-benzoylpiperidine hydrochloride;

4-[N-(1,2,3,4-tetrahydronaphthalen-2-yl)-N-methyl]aminomethyl-1-benzoylpiperidine hydrochloride; or 4-[N-(1,2,3,4-tetrahydronaphthalen-2-yl)-N-propyl]aminomethyl-1-benzoylpiperidine hydrochloride.
4. A process for the preparation of a compound as claimed in claim 1, 2 or 3, which comprises reacting a primary amine of general formula (II) (II) (in which n is as defined in Claim 1), which may be in the form of an acid addition salt, (a) with an alkyl or benzyl chloroformate; or (b) with a C2 or C3 acid chloride;
reducing the carbamate (a) or the amide (b) thus obtained to give a secondary amine of general formula (III) (III) (in which R is as defined in Claim 1), and reacting this secondary amine with a tosylate of general formula (IV) (IV) (in which Ts represents a (4-methylphenyl)sulphonyl group and X is as defined in Claim 1), if appropriate in the presence of an organic or inorganic base, and if desired converting a free base of formula I into an acid addition salt.
5. A pharmaceutical composition comprising as active ingredient a compound as claimed in claim 1, 2 or 3.
6. A compound as claimed in claim 1, 2 or 3, for use in the treatment of a disease or condition directly or indirectly involving the 5-HT1A type serotoninergic receptors.
CA002037610A 1990-03-07 1991-03-06 Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application Abandoned CA2037610A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9002855A FR2659323B1 (en) 1990-03-07 1990-03-07 DERIVATIVES OF 4- (AMINOMETHYL) PIPERIDINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
FR90.02855 1990-03-07

Publications (1)

Publication Number Publication Date
CA2037610A1 true CA2037610A1 (en) 1991-09-08

Family

ID=9394458

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002037610A Abandoned CA2037610A1 (en) 1990-03-07 1991-03-06 Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application

Country Status (15)

Country Link
US (1) US5179108A (en)
EP (1) EP0447292A1 (en)
JP (1) JPH04217663A (en)
KR (1) KR910016695A (en)
AU (1) AU632669B2 (en)
CA (1) CA2037610A1 (en)
FI (1) FI911133A (en)
FR (1) FR2659323B1 (en)
HU (1) HUT57723A (en)
IE (1) IE910747A1 (en)
IL (1) IL97447A0 (en)
NO (1) NO910874L (en)
NZ (1) NZ237340A (en)
PT (1) PT96952A (en)
ZA (1) ZA911650B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681320B1 (en) * 1991-09-12 1994-01-14 Synthelabo DERIVATIVES OF N- (4,7DIMETHOXYINDAN-2-YL) -1- (PHENYLCARBONYL) -N-PROPYL-PIPERIDINE-4-METHANAMINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
FR2681325B1 (en) * 1991-09-16 1993-12-17 Fabre Medicament Pierre DERIVATIVES OF AMINOMETHYL-4 PIPERIDINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
FR2701479B1 (en) * 1993-02-11 1995-05-12 Pf Medicament New heterocyclic derivatives of 4-aminomethyl piperidine, their preparation and their therapeutic use.
FR2769628B1 (en) * 1997-10-09 1999-11-12 Synthelabo DERIVATIVES OF N- (2,3-DIHYDRO-1H-INDEN-2-YL) -N-PROPYL-8- AZABICYCLO [3.2.1.] OCTANE-3-METHANAMINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
UA58476C2 (en) * 1997-10-09 2003-08-15 Санофі-Сентелябо 8-AZABICYCLO[3.2.1]OCTANE-3-METHANAMINE DERIVATIVES, ITS PREPARATION AND APPLICATION IN therapeutics
US6777554B2 (en) 2001-02-05 2004-08-17 Teva Pharmaceutical Industries Ltd. Preparation of N-methylparoxetine and related intermediate compounds
DE60238709D1 (en) 2001-12-03 2011-02-03 Hoffmann La Roche 4-PIPERIDINYL ALKYLAMINE DERIVATIVES, ANTAGONISTS OF MUSCARIN RECEPTORS
CA2469055C (en) 2001-12-03 2011-03-29 F. Hoffmann-La Roche Ag Aminotetralin derivatives as muscarinic receptor antagonists
DE60230683D1 (en) * 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO-3.1.0 HEXAN DERIVATIVE
US7488748B2 (en) * 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089898A1 (en) * 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (en) * 2003-04-11 2006-04-11 Ranbaxy Lab Ltd azabicyclic derivatives as muscarinic receptor antagonists, method for their preparation and pharmaceutical composition containing them
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
EP1828126A1 (en) * 2004-12-15 2007-09-05 Ranbaxy Laboratories Limited Acid addition salts of muscarinic receptor antagonists
EP1888525A1 (en) * 2005-05-03 2008-02-20 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives as muscarinic receptor antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250719A (en) * 1969-03-19 1971-10-20
FR2484415A1 (en) * 1980-06-13 1981-12-18 Pharmindustrie NOVEL INDENE DERIVATIVES, METHODS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS
US4564628A (en) * 1983-01-03 1986-01-14 Nelson Research & Development Co. Substituted 2-aminotetralins
FI95572C (en) * 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt

Also Published As

Publication number Publication date
NO910874L (en) 1991-09-09
FR2659323A1 (en) 1991-09-13
AU7267091A (en) 1991-09-12
FR2659323B1 (en) 1992-06-12
ZA911650B (en) 1991-12-24
NO910874D0 (en) 1991-03-06
NZ237340A (en) 1992-11-25
FI911133A (en) 1991-09-08
PT96952A (en) 1991-10-31
EP0447292A1 (en) 1991-09-18
FI911133A0 (en) 1991-03-06
HU910731D0 (en) 1991-09-30
JPH04217663A (en) 1992-08-07
US5179108A (en) 1993-01-12
KR910016695A (en) 1991-11-05
HUT57723A (en) 1991-12-30
IE910747A1 (en) 1991-09-11
AU632669B2 (en) 1993-01-07
IL97447A0 (en) 1992-06-21

Similar Documents

Publication Publication Date Title
US5885985A (en) Guanidine derivatives useful in therapy
EP0100200B1 (en) 2-substituted 4-amino-6,7-dimethoxyquinolines
US5179108A (en) Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application
US5143916A (en) Naphthylpiperazines useful as 5-ht1a receptor ligands
CZ282919B6 (en) Novel n-alkylene piperidine derivatives, process of their preparation, intermediate for their preparation and pharmaceutical compositions containing such derivatives
WO1996026196A2 (en) Benzylpiperidines and piperazines as muscarinic antagonists
CA1295616C (en) Antiarrhythmic agents
IE882179L (en) N,n-disubstituted arylamides
US4950670A (en) 6-phenyl-3-(piperazinyalalkyl)-2,4(1H,3H)-pyrimidinedione derivatives, their preparation and their application in therapy
US5486518A (en) 4-indolylpiperazinyl derivatives
US4243666A (en) 4-Amino-2-piperidino-quinazolines
MXPA05010288A (en) Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain.
US5519025A (en) 4-indolylpiperazinyl derivatives
KR20030024919A (en) N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide
US5272157A (en) Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application
US5096900A (en) (4-piperidyl)methyl-2,3-dihydro-1h-isoindole and -2,3,4,5-tetrahydro-1h-benzazepine derivatives, their preparation and their application in therapy
FI57937C (en) PROCEDURE FOR THE PHARMACOLOGICAL PROPERTIES OF VAERDEFULLA 3- (1-PIPERAZINYLALKYL) -2,4-QUINAZOLINDION-FOERENINGAR
CA2038962A1 (en) Aminobenzene compounds, their production and use
CA1285945C (en) N-¬¬¬1-(2)naphthylenemethyl or quinol-6-ylmethyl)-4- piperidinyl|amino|-carbonyl|-6-quinolinecarboxamide compounds
EP0247345A2 (en) 1,4-Dihydropyridine-3,5-dicarboxylates incorporating an alkyleneaminoalkylene-heteroatom moiety
JPH05271208A (en) 1,4-benzothiazepine derivative
JPH037280A (en) Novel benzothiopyranylamine
US4931449A (en) 2-((4-piperidyl)methyl)benzofuro(2,3-C)pyridine derivatives, and their application in therapy
JPH05201978A (en) N-(4,7-dimethoxy-2-indanyl)-1-(phenylcarbonyl)-n-propyl-4- piperidinemethaneamine derivative,its production,and its use as medicine
US5162321A (en) 1-naphthyl piperazines useful as 5-HT1A receptor ligands

Legal Events

Date Code Title Description
FZDE Discontinued